-
-
Login
A look at the company's dramatic share price drop, iLet patient Numbers, CGM partnership with Abbott & the outlook for rollout in the UK/EU.
We reflect on Dexcom's performance in 2025 and get up-to-date with news of their plans for a G8 sensor and international expansion.
FDA Commissioner Martin Makary recently highlighted the role of CGMs in preventing chronic conditions, questioning why they are only available on prescription. Could there be any benefit to the diabetes community of a policy change?
New medtech startup, Luna Health, based in the US, have raised $23.6 million to advance a patch pump designed specifically for overnight use only.
News that Eversense 365 has been named Best New Technology Solution for Diabetes Management in the 2025.
News that approval from the FDA of the Dexcom G7 15 day CGM in the US, with a grace period of 12 hours, makes this the longest lasting CGM.
Breaking news! Abbott stripped of sensor's 3D trade mark!
A new CGM launches this February in the UK.
News that Abbott and Dexcom have agreed not to sue each other for patents relating to their CGM tech for another 10 years.
How to 'Go Bionic' with the iLet Bionic Pancreas.
Tidepool announce they will integrate with Abbott's Freestyle Libre portfolio for seamless cloud-to-cloud data.
